JPH08301754A - Ｎａイオン非依存性Ｃｌイオン／炭酸水素イオン交換体と関連する疾患の治療用医薬組成物 - Google Patents

Ｎａイオン非依存性Ｃｌイオン／炭酸水素イオン交換体と関連する疾患の治療用医薬組成物

Info

Publication number: JPH08301754A
Authority: JP; Japan
Prior art keywords: alkyl; formula; exchanger; hco; dihydro
Prior art date: 1995-05-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP8111572A

Other languages

English (en)

Japanese (ja)

Inventor

Ludovic Durand

リュドヴィス・デュラン

Jean-Paul Babingui

ジャン−ポール・バビンギ

Claudie Moulin

クローディ・ムラン

Sylvie Robert-Piessard

シルビー・ロベール−ピエサール

Baut Guillaume Le

ギョーム・ル・ボート

Elisabeth Scalbert

エリザベス・スカルベール

Daniel-Henri Caignard

ダニエル−アンリ・カニャール

Pierre Renard

ピエール・レナール

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

ADIR SARL

Original Assignee

ADIR SARL

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-05-05

Filing date

1996-05-02

Publication date

1996-11-19

1996-05-02 Application filed by ADIR SARL filed Critical ADIR SARL

1996-11-19 Publication of JPH08301754A publication Critical patent/JPH08301754A/ja

Status Pending legal-status Critical Current

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 13
201000010099 disease Diseases 0.000 title claims abstract description 10
239000000203 mixture Substances 0.000 title abstract description 5
239000003814 drug Substances 0.000 title description 2
229940079593 drug Drugs 0.000 title description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 title 1
230000001419 dependent effect Effects 0.000 title 1
GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 title 1
229910001415 sodium ion Inorganic materials 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 34
125000000217 alkyl group Chemical group 0.000 claims abstract description 23
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
208000028867 ischemia Diseases 0.000 claims abstract description 11
229910052736 halogen Inorganic materials 0.000 claims abstract description 10
150000002367 halogens Chemical class 0.000 claims abstract description 9
208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 4
206010003119 arrhythmia Diseases 0.000 claims abstract description 4
230000006793 arrhythmia Effects 0.000 claims abstract description 4
206010002383 Angina Pectoris Diseases 0.000 claims abstract description 3
125000004448 alkyl carbonyl group Chemical group 0.000 claims abstract description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 3
239000004480 active ingredient Substances 0.000 claims abstract 6
125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 claims abstract 4
-1 [1] -benzopyran-2 -Yl Chemical class 0.000 claims description 21
229910052739 hydrogen Inorganic materials 0.000 claims description 11
239000001257 hydrogen Substances 0.000 claims description 11
150000003839 salts Chemical class 0.000 claims description 9
238000000034 method Methods 0.000 claims description 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
125000003545 alkoxy group Chemical group 0.000 claims description 7
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 6
230000000144 pharmacologic effect Effects 0.000 claims description 6
206010020772 Hypertension Diseases 0.000 claims description 4
108010029485 Protein Isoforms Proteins 0.000 claims description 4
102000001708 Protein Isoforms Human genes 0.000 claims description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
230000002526 effect on cardiovascular system Effects 0.000 claims description 4
150000002431 hydrogen Chemical class 0.000 claims description 4
230000002265 prevention Effects 0.000 claims description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
201000001320 Atherosclerosis Diseases 0.000 claims description 2
206010019280 Heart failures Diseases 0.000 claims description 2
206010020880 Hypertrophy Diseases 0.000 claims description 2
125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims description 2
125000004181 carboxyalkyl group Chemical group 0.000 claims description 2
230000003463 hyperproliferative effect Effects 0.000 claims description 2
125000003884 phenylalkyl group Chemical group 0.000 claims description 2
208000037803 restenosis Diseases 0.000 claims description 2
238000012163 sequencing technique Methods 0.000 claims description 2
238000010367 cloning Methods 0.000 claims 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical group C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
208000017169 kidney disease Diseases 0.000 abstract description 5
206010048962 Brain oedema Diseases 0.000 abstract description 4
208000006752 brain edema Diseases 0.000 abstract description 4
208000024827 Alzheimer disease Diseases 0.000 abstract description 3
208000020084 Bone disease Diseases 0.000 abstract description 3
206010016654 Fibrosis Diseases 0.000 abstract description 3
208000019693 Lung disease Diseases 0.000 abstract description 3
239000002246 antineoplastic agent Substances 0.000 abstract description 3
230000003013 cytotoxicity Effects 0.000 abstract description 3
231100000135 cytotoxicity Toxicity 0.000 abstract description 3
230000004761 fibrosis Effects 0.000 abstract description 3
208000007342 Diabetic Nephropathies Diseases 0.000 abstract description 2
208000001132 Osteoporosis Diseases 0.000 abstract description 2
206010003246 arthritis Diseases 0.000 abstract description 2
150000001562 benzopyrans Chemical class 0.000 abstract description 2
206010012601 diabetes mellitus Diseases 0.000 abstract description 2
208000033679 diabetic kidney disease Diseases 0.000 abstract description 2
208000000718 duodenal ulcer Diseases 0.000 abstract description 2
230000000302 ischemic effect Effects 0.000 abstract description 2
208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
208000007107 Stomach Ulcer Diseases 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
201000005917 gastric ulcer Diseases 0.000 abstract 1
230000000472 traumatic effect Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 18
238000002844 melting Methods 0.000 description 17
230000008018 melting Effects 0.000 description 17
230000000694 effects Effects 0.000 description 15
239000011734 sodium Substances 0.000 description 15
241000700159 Rattus Species 0.000 description 12
230000003834 intracellular effect Effects 0.000 description 11
239000002585 base Substances 0.000 description 9
150000003857 carboxamides Chemical class 0.000 description 8
210000004413 cardiac myocyte Anatomy 0.000 description 6
210000001130 astrocyte Anatomy 0.000 description 5
210000002997 osteoclast Anatomy 0.000 description 5
238000012360 testing method Methods 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
208000005223 Alkalosis Diseases 0.000 description 4
208000012639 Balance disease Diseases 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
230000002340 alkalosis Effects 0.000 description 4
210000000988 bone and bone Anatomy 0.000 description 4
208000031225 myocardial ischemia Diseases 0.000 description 4
230000020477 pH reduction Effects 0.000 description 4
239000003826 tablet Substances 0.000 description 4
208000010444 Acidosis Diseases 0.000 description 3
208000006386 Bone Resorption Diseases 0.000 description 3
208000002249 Diabetes Complications Diseases 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000007950 acidosis Effects 0.000 description 3
208000026545 acidosis disease Diseases 0.000 description 3
230000024279 bone resorption Effects 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
208000014674 injury Diseases 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
230000002861 ventricular Effects 0.000 description 3
XKYBBEIKECMPNB-UHFFFAOYSA-N 6-hydroxy-2,5,7,8-tetramethyl-n-(2,4,5-trimethylphenyl)-3,4-dihydrochromene-2-carboxamide Chemical compound C1=C(C)C(C)=CC(C)=C1NC(=O)C1(C)OC2=C(C)C(C)=C(O)C(C)=C2CC1 XKYBBEIKECMPNB-UHFFFAOYSA-N 0.000 description 2
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
206010012655 Diabetic complications Diseases 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
206010021143 Hypoxia Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
230000009858 acid secretion Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000011575 calcium Substances 0.000 description 2
150000003943 catecholamines Chemical class 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000003792 electrolyte Substances 0.000 description 2
210000001339 epidermal cell Anatomy 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
230000007954 hypoxia Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000012105 intracellular pH reduction Effects 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000008733 trauma Effects 0.000 description 2
230000002485 urinary effect Effects 0.000 description 2
208000003663 ventricular fibrillation Diseases 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
ITWDZLGSZLGAOV-UHFFFAOYSA-N 2-[(6-acetyloxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carbonyl)amino]-3,5-dimethylbenzoic acid Chemical compound C1CC2=C(C)C(OC(=O)C)=C(C)C(C)=C2OC1(C)C(=O)NC1=C(C)C=C(C)C=C1C(O)=O ITWDZLGSZLGAOV-UHFFFAOYSA-N 0.000 description 1
RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 1
ZCJALIIOYBRDHT-UHFFFAOYSA-N 6-hydroxy-2,5,7,8-tetramethyl-n-(2,4,6-trimethylphenyl)-3,4-dihydrochromene-2-carboxamide Chemical compound CC1=CC(C)=CC(C)=C1NC(=O)C1(C)OC2=C(C)C(C)=C(O)C(C)=C2CC1 ZCJALIIOYBRDHT-UHFFFAOYSA-N 0.000 description 1
LIWTVWNNVJULQC-UHFFFAOYSA-N 6-hydroxy-2,5,7,8-tetramethyl-n-(3,4,5-trimethoxyphenyl)-3,4-dihydrochromene-2-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(NC(=O)C2(C)OC3=C(C)C(C)=C(O)C(C)=C3CC2)=C1 LIWTVWNNVJULQC-UHFFFAOYSA-N 0.000 description 1
HPAWKDMFKGMZPJ-UHFFFAOYSA-N 6-hydroxy-5,7,8-trimethyl-n-(2,4,5-trimethylphenyl)-3,4-dihydro-2h-chromene-2-carboxamide Chemical compound C1=C(C)C(C)=CC(C)=C1NC(=O)C1OC2=C(C)C(C)=C(O)C(C)=C2CC1 HPAWKDMFKGMZPJ-UHFFFAOYSA-N 0.000 description 1
ZYFBOIXKOFMKFY-UHFFFAOYSA-N 6-hydroxy-n-(4-hydroxy-2,3-dimethylphenyl)-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide Chemical compound CC1=C(O)C=CC(NC(=O)C2(C)OC3=C(C)C(C)=C(O)C(C)=C3CC2)=C1C ZYFBOIXKOFMKFY-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
102000005862 Angiotensin II Human genes 0.000 description 1
101800000733 Angiotensin-2 Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010070918 Bone deformity Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241001313846 Calypso Species 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
208000032544 Cicatrix Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000010837 Diabetic eye disease Diseases 0.000 description 1
206010051153 Diabetic gastroparesis Diseases 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
206010017886 Gastroduodenal ulcer Diseases 0.000 description 1
206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108091006671 Ion Transporter Proteins 0.000 description 1
102000037862 Ion Transporter Human genes 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
206010042220 Stress ulcer Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
NDOVCQPWXYFNBA-UHFFFAOYSA-N [2,5,7,8-tetramethyl-2-[(2,4,5-trimethylphenyl)carbamoyl]-3,4-dihydrochromen-6-yl] acetate Chemical compound C1CC2=C(C)C(OC(=O)C)=C(C)C(C)=C2OC1(C)C(=O)NC1=CC(C)=C(C)C=C1C NDOVCQPWXYFNBA-UHFFFAOYSA-N 0.000 description 1
XDMUUWDGEBWAER-UHFFFAOYSA-N [2,5,7,8-tetramethyl-2-[(2,4,6-trimethylphenyl)carbamoyl]-3,4-dihydrochromen-6-yl] acetate Chemical compound C1CC2=C(C)C(OC(=O)C)=C(C)C(C)=C2OC1(C)C(=O)NC1=C(C)C=C(C)C=C1C XDMUUWDGEBWAER-UHFFFAOYSA-N 0.000 description 1
XBQKIGIOJKEPDF-UHFFFAOYSA-N [2,5,7,8-tetramethyl-2-[(3,4,5-trimethoxyphenyl)carbamoyl]-3,4-dihydrochromen-6-yl] acetate Chemical compound COC1=C(OC)C(OC)=CC(NC(=O)C2(C)OC3=C(C)C(C)=C(OC(C)=O)C(C)=C3CC2)=C1 XBQKIGIOJKEPDF-UHFFFAOYSA-N 0.000 description 1
MWVHSMGGGZVGBJ-UHFFFAOYSA-N [5,7,8-trimethyl-2-[(2,4,5-trimethylphenyl)carbamoyl]-3,4-dihydro-2h-chromen-6-yl] acetate Chemical compound C1CC2=C(C)C(OC(=O)C)=C(C)C(C)=C2OC1C(=O)NC1=CC(C)=C(C)C=C1C MWVHSMGGGZVGBJ-UHFFFAOYSA-N 0.000 description 1
WYJUSFQQFMKHHL-UHFFFAOYSA-N [5,7,8-trimethyl-2-[(3,4,5-trimethoxyphenyl)carbamoyl]-3,4-dihydro-2h-chromen-6-yl] acetate Chemical compound COC1=C(OC)C(OC)=CC(NC(=O)C2OC3=C(C)C(C)=C(OC(C)=O)C(C)=C3CC2)=C1 WYJUSFQQFMKHHL-UHFFFAOYSA-N 0.000 description 1
YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical class [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229950006323 angiotensin ii Drugs 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000003501 anti-edematous effect Effects 0.000 description 1
230000003440 anti-fibrillation Effects 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000003140 astrocytic effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000002805 bone matrix Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
230000003293 cardioprotective effect Effects 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
210000002987 choroid plexus Anatomy 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000003086 colorant Substances 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000006735 deficit Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000003617 erythrocyte membrane Anatomy 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
235000011194 food seasoning agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
230000027119 gastric acid secretion Effects 0.000 description 1
210000001914 gastric parietal cell Anatomy 0.000 description 1
201000000052 gastrinoma Diseases 0.000 description 1
231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
230000037417 hyperactivation Effects 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000004941 influx Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
230000003914 insulin secretion Effects 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
235000001055 magnesium Nutrition 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
210000003584 mesangial cell Anatomy 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
210000000110 microvilli Anatomy 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
230000007472 neurodevelopment Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000009207 neuronal maturation Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
239000002674 ointment Substances 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
210000001711 oxyntic cell Anatomy 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
208000000689 peptic esophagitis Diseases 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000005588 protonation Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000001696 purinergic effect Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000021014 regulation of cell growth Effects 0.000 description 1
230000020988 regulation of intracellular pH Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000037387 scars Effects 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000000580 secretagogue effect Effects 0.000 description 1
DYPYMMHZGRPOCK-UHFFFAOYSA-N seminaphtharhodafluor Chemical compound O1C(=O)C2=CC=CC=C2C21C(C=CC=1C3=CC=C(O)C=1)=C3OC1=CC(N)=CC=C21 DYPYMMHZGRPOCK-UHFFFAOYSA-N 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
210000005239 tubule Anatomy 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Rheumatology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrane Compounds (AREA)

JP8111572A 1995-05-05 1996-05-02 Ｎａイオン非依存性Ｃｌイオン／炭酸水素イオン交換体と関連する疾患の治療用医薬組成物 Pending JPH08301754A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9505361A FR2733685B1 (fr)	1995-05-05	1995-05-05	Utilisation des derives du benzopyrane pour l'obtention de compositions pharmaceutiques destinees au traitement des pathologies liees a l'echangeur c1-/hc03-, na+ independant
FR9505361		1995-05-05

Publications (1)

Publication Number	Publication Date
JPH08301754A true JPH08301754A (ja)	1996-11-19

Family

ID=9478712

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP8111572A Pending JPH08301754A (ja)	1995-05-05	1996-05-02	Ｎａイオン非依存性Ｃｌイオン／炭酸水素イオン交換体と関連する疾患の治療用医薬組成物

Country Status (9)

Country	Link
US (1)	US5703118A (fr)
EP (1)	EP0740936A3 (fr)
JP (1)	JPH08301754A (fr)
CN (1)	CN1136920A (fr)
AU (1)	AU5204396A (fr)
CA (1)	CA2175747A1 (fr)
FR (1)	FR2733685B1 (fr)
NO (1)	NO961797L (fr)
ZA (1)	ZA963520B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6008208A (en) *	1995-10-23	1999-12-28	Osteoscreen, Inc.	Compositions and methods for treating bone deficit conditions
WO1998017267A1 (fr) *	1996-10-23	1998-04-30	Zymogenetics, Inc.	Compositions et methodes pour traiter les etats associes a un deficit osseux
FR2756284B1 (fr) *	1996-11-26	2000-04-28	Adir	Nouveaux derives du benzopyrane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1206442A4 (fr) *	1999-08-24	2004-12-29	Univ Virginia Commonwealth	Modificateurs allosteriques chiraux substitues d'hemoglobine
FI20011507A0 (fi) *	2001-07-10	2001-07-10	Orion Corp	Uusia yhdisteitä
WO2004000312A2 (fr)	2002-06-19	2003-12-31	Solvay Pharmaceuticals Gmbh	Medicament pour traiter des affections impliquant une inhibition ou une baisse d'activite de proteines transporteuses de bicarbonate regulant le ph
FI20030030A0 (fi) *	2003-01-09	2003-01-09	Orion Corp	Uusia yhdisteitä
US20070259966A1 (en) *	2004-04-22	2007-11-08	Allos Therapeutics, Inc.	Coadministration of Radiation, Efaproxiral Sodium, and Supplemental Oxygen for the Treatment of Cancer
US8349066B2 (en) *	2006-09-21	2013-01-08	Ppg Industries Ohio, Inc.	Low temperature, moisture curable coating compositions and related methods
CN101274765B (zh) *	2007-03-30	2011-11-30	中国石油化工股份有限公司	一种含贵金属的微孔钛硅材料及其制备方法
CN104250253B (zh) *	2014-09-12	2017-04-05	辽宁大学	取代四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1338012C (fr) *	1987-04-27	1996-01-30	John Michael Mccall	Amines possedant des proprietes pharmaceutiques
JPH02215778A (ja) *	1989-02-14	1990-08-28	Kuraray Co Ltd	３，４―ジヒドロ―２ｈ―ベンゾピラン誘導体及びその医薬用途
US5099012A (en) *	1990-12-11	1992-03-24	Eastman Kodak Company	Chroman-2-carboxamide conjugates and their use for treatment of reperfusion injury
JP3053490B2 (ja) *	1991-02-25	2000-06-19	杏林製薬株式会社	チアゾリジン−２，４−ジオン誘導体とその塩及び製造法
FR2676056B1 (fr) *	1991-05-03	1993-07-16	Adir	Nouveaux derives du benzopyranne leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

1995
- 1995-05-05 FR FR9505361A patent/FR2733685B1/fr not_active Expired - Fee Related
1996
- 1996-05-02 EP EP96400931A patent/EP0740936A3/fr not_active Withdrawn
- 1996-05-02 JP JP8111572A patent/JPH08301754A/ja active Pending
- 1996-05-03 NO NO961797A patent/NO961797L/no not_active Application Discontinuation
- 1996-05-03 AU AU52043/96A patent/AU5204396A/en not_active Abandoned
- 1996-05-03 US US08/643,257 patent/US5703118A/en not_active Expired - Fee Related
- 1996-05-03 ZA ZA963520A patent/ZA963520B/xx unknown
- 1996-05-03 CN CN96104494A patent/CN1136920A/zh active Pending
- 1996-05-03 CA CA002175747A patent/CA2175747A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
US5703118A (en)	1997-12-30
FR2733685A1 (fr)	1996-11-08
NO961797L (no)	1996-11-06
CN1136920A (zh)	1996-12-04
FR2733685B1 (fr)	1997-05-30
EP0740936A2 (fr)	1996-11-06
AU5204396A (en)	1996-11-14
NO961797D0 (no)	1996-05-03
EP0740936A3 (fr)	1997-01-15
ZA963520B (en)	1996-11-13
CA2175747A1 (fr)	1996-11-06

Publication	Publication Date	Title
JP2010031059A (ja)	2010-02-12	筋萎縮性側索硬化症を処置するためのプラミペキソールの使用
JP6010196B2 (ja)	2016-10-19	オキサゾリジノン含有二量体化合物、組成物、ならびに作製および使用方法
WO2011135303A2 (fr)	2011-11-03	Modulateurs d'ubiquitination
JPH08301754A (ja)	1996-11-19	Ｎａイオン非依存性Ｃｌイオン／炭酸水素イオン交換体と関連する疾患の治療用医薬組成物
CN105367485A (zh)	2016-03-02	用于预防和/或治疗中枢神经系统退行性失调的新颖组合物
US11345654B2 (en)	2022-05-31	Polymorphic compounds and uses thereof
US20070249562A1 (en)	2007-10-25	Treatment of atrial fibrillation
WO2002017913A1 (fr)	2002-03-07	Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque
US20230136792A1 (en)	2023-05-04	Compositions and methods for treating age-related diseases and premature aging disorders
US20070265279A1 (en)	2007-11-15	Use of mGluR5 antagonists for the treatment of pruritic conditions
WO2007059631A1 (fr)	2007-05-31	Dosage selectionne pour le traitement de pathologies cardiovasculaires et apparentees
EP2409698A1 (fr)	2012-01-25	Utilisation d'un acide indazoleméthoxyalcanoïque pour la préparation d'une composition pharmaceutique
US20160000746A1 (en)	2016-01-07	Pharmaceutical compositions and methods for treating age-related macular degeneration with melatonin analogues
JPH01299283A (ja)	1989-12-04	新規アルカノフェノン類
US20120010264A1 (en)	2012-01-12	Novel medicament for treating cognitive impairment
JP2000273040A (ja)	2000-10-03	トログリタゾンを含有するアポトーシス抑制剤
AU2004295178A1 (en)	2005-06-16	Therapeutics use of pyridinium compounds to modulate NAADP activity
SG11202111877TA (en)	2021-11-29	Method for treating cough by using diaminopyrimidine compound
JP2987727B2 (ja)	1999-12-06	ジフェニルボラン誘導体を有効成分として含有する内因性カルシウム放出抑制剤
JP5079503B2 (ja)	2012-11-21	ラジカルスカベンジャー及び活性酸素消去剤
TW200403988A (en)	2004-03-16	Use of inhibitors of the sodium/hydrogen exchanger for the treatment of thrombotic and inflammatory disorders
MX2010010869A (es)	2010-11-12	Agente para prevenir y/o tratar enfermedades vasculares.
EP1496057A1 (fr)	2005-01-12	Nouveau cristal d'anhydride de derive de quinoxalinedione
WO2024097285A1 (fr)	2024-05-10	Modulateurs de l'activité de mtorc1 et leurs utilisations
WO2007137409A1 (fr)	2007-12-06	Traitement et prévention d'un déclin cognitif